低セプシン発現は,管腺がんにおけるゲムシタビンベースの新補助療法に対するよりよい反応と関連している
Oncology
|August 28, 2025
まとめ
ヘプシン発現は臓がん患者の生存に影響を与えなかった. しかし,ゲムシタビンベースの化学療法を受けた患者では, neoadjuvant 療法後に,より弱いセプシン発現がよりよい治療反応と相関していました.
科学分野:
- 腫瘍学
- 分子生物学
- 生物化学
背景:
- ヘプシンという2型トランスメブランセリンプロテアゼ (TTSP) は細胞外マトリックスを分解し,細胞マトリックス相互作用に影響を与えます.
- 癌の侵入と転移におけるヘプシンの役割は認められているが,臓がんにおけるその機能は未研究である.
- この研究では,臓管内腺がんにおけるセプシンの発現と臨床的重要性を調査しています.
研究 の 目的:
- 管腺がん (PDAC) 組織におけるセプシン発現を検査する.
- 臨床病理学的パラメータと患者のアウトカムと相関する.
- ネオアジュバン療法を受けている患者におけるセプシンの作用を評価する.
主な方法:
- 223人のPDAC患者における組織マイクロアレイと免疫ヒストケミストリーの解析.
- 様々な臨床病理学的要因に対するセプシン発現の強度の評価.
- ネオアジュバント療法を受けた66人の患者の別々の分析,治療への反応を含む.
主要な成果:
- 67% の非ネオアジュバント患者と 42% のネオアジュバント患者で強いセプシン発現が見られた.
- ヘプシン発現は,いずれの患者群でも全生存期間と相関しなかった.
- ネオアジュバントで治療された患者では,強いセプシン発現は,下位Tステージと上位Nステージに関連していた. ゲムシタビンベースの化学療法に対するよりよい反応と相関している.
結論:
- ゲムシタビンベースのネオアジュヴァント治療を受けている臓がん患者の治療反応の改善と関連している.
- ヘプシン発現は,ネオアジュバント治療に関係なく,臓がんの生存率の予後要因であるようには見えません.
- 臓がん治療への反応におけるセプシンの特定の役割は,さらなる研究によって明らかになるかもしれない.
さらに関連する動画
08:30Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
Published on: October 9, 2018
12.5K
07:08Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
903
関連する概念動画
Transducer Mechanism: Enzyme-Linked Receptors
4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
619
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
619
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
618
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
618
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
